This independent medical education activity features an expert discussion between Jedd D. Wolchok, MD, PhD, and Axel Hauschild, MD, focusing on two recent publications regarding the use of ipilimumab in the management of metastatic melanoma. (Hodi FS, et al. N Engl J Med. 2010;363(8):711-723. Robert C, et al. N Engl J Med. 2011;364(26):2517-2526.)
Drs Wolchok and Hauschild discuss two phase III trials evaluating the immunotherapy ipilimumab as a treatment for melanoma: ipilimumab monotherapy in the relapsed/refractory setting and ipilimumab in combination with dacarbazine for previously untreated metastatic melanoma. They explain the designs and outcomes of these trials and analyze the effect of these data on clinical practice.
Learning Objectives
After successful completion of this educational activity, participants should be able to:
Evaluate the latest management approaches for patients with melanoma, including the efficacy and safety of available therapies
Discuss adverse events associated with the use of immunotherapies for the treatment of melanoma and review appropriate strategies to manage these events
Integrate recent clinical trial data into appropriate management strategies that result in improved outcomes for patients with melanoma
Audience
This educational activity is designed for medical and surgical oncologists, dermatologists, and other
healthcare providers involved or interested in the treatment of patients with melanoma.
Support
Support for this educational activity is provided by Bristol-Myers Squibb.
